Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient Epcoritamab in Large B-cell Lymphoma
NCT06811272Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Massachusetts General Hospital. Started Jun 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06811272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811272.